What Pharma Manufacturers Need to Know About the New “One Big Beautiful Bill Act” (OBBBA)

Key Takeaways from the Latest Regulatory Reforms Impacting Medicaid, Medicare, and Drug Pricing

On July 4, 2025, the “One Big Beautiful Bill Act” (OBBBA) was signed into law, bringing changes to Medicaid, Medicare, and federal drug pricing policy. While the legislation is broad in scope, many of its provisions may have direct implications for pharmaceutical and biotechnology manufacturers —particularly those participating in government programs like Medicaid and Medicare.

In this blog, we break down what pharma manufacturers need to know — not a full legislative walkthrough, rather a concise overview of how these regulatory shifts could affect drug reimbursement, rebate obligations, and future compliance planning.

MEDICAID HIGHLIGHTS FOR PHARMA MANUFACTURERS:

Enrollment Verification Measures: States must routinely cross-check beneficiary data across federal and state systems to reduce duplicate or ineligible enrollees. This could result in a smaller covered population — and fewer Medicaid-paid prescriptions.
Eligibility Redeterminations: Starting in 2027, most Medicaid recipients will be subject to automated eligibility checks every 6 months, increasing program churn.
Non-Citizen Restrictions: Medicaid eligibility will be further restricted for certain non-citizen populations starting in late 2026.
Accountability for Overpayments: Beginning in 2030, states may face financial penalties if they don’t resolve identified Medicaid overpayments — adding pressure that may trickle down to manufacturers through tighter rebate enforcement.
Increased Member Responsibility: States are authorized to impose work requirements and modify cost-sharing rules for expansion populations, which could affect program participation and access trends.

MEDICARE UPDATES FOR PHARMA MANUFACTURERS:

The bill also introduces Medicare reforms that align eligibility rules more closely with Medicaid and clarify how certain drugs will be treated under federal pricing controls.

What stands out for pharma:

Tighter Enrollment Rules: Medicare will adopt stricter residency and legal presence requirements, which may limit growth in covered beneficiaries.
Orphan Drug Carveout: Notably, the legislation reaffirms that certain orphan drugs — used to treat rare diseases — are excluded from Medicare’s Drug Price Negotiation Program. This helps maintain critical incentives and opportunities for manufacturers of orphan drugs to recoup development costs to encourage further innovation in rare disease treatment.

BOTTOM LINE FOR PHARMA MANUFACTURERS

While many of OBBBA’s changes focus on program integrity and eligibility enforcement, they may have downstream effects for drug manufacturers:

Expect increased fluctuation in Medicaid enrollment, which may impact rebate liabilities and forecasting.
Heightened data validation and oversight could lead to more rebate audits and compliance inquiries.
Exempting orphan drugs from Medicare price negotiations is a positive sign for all people affected by rare diseases, especially provided that the United States has historically been one of the leading countries for rare disease treatment development. This will help keep costs as low as possible for affected individuals and reduce additional expense worries for companies focused on rare disease R&D.

NAVIGATING THE NEW COMPLIANCE ENVIRONMENT

As federal policy continues to evolve, manufacturers must stay agile in adapting their government pricing and market access strategies. Our team helps life sciences companies navigate complex compliance landscapes — including Medicaid, Medicare, VA, and Tricare program participation — while minimizing risk and protecting revenue.

Contact us today to discuss how these changes may affect your products, pricing, and long-term strategy.

Sources

U.S. Congress – H.R.1 – One Big Beautiful Bill Act (2025)

Hogan Lovells – One Big Beautiful Bill Act: What’s In It for Health? (2025)

Sally Pipes, Forbes – The Big Beautiful Bill Fixes One Drug Problem but Highlights an Even Bigger One (July 21, 2025)